First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
"Our innovative approach to drug discovery is gaining traction, and we are excited about the potential of our lead candidates."
Moat: Compugen's proprietary computational platform provides a unique advantage in identifying novel drug candidates.
growth - Investors are likely attracted to the high revenue growth potential and innovative drug pipeline.
Moderate - Rising interest rates could increase the cost of capital for future funding rounds, but the company is currently low on debt…
Watch on earnings: Clinical trial results for CGEN-15001T, Number of new partnerships formed, Revenue growth from collaborations.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $10M to $16M as cgen-15001t shows promising early-stage clinical trial results, with a 75% response rate in initial cohorts.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.